Pregnenolone heads the steroid pathway and shifts brain balance toward alertness. Benefits — less craving, less chronic back pain, better everyday functioning — come from small trials in people with specific diagnoses, at doses far above supplement labels. No study tested undiagnosed adults, none ran past twelve weeks, and the age-decline premise is contested. Harms: overstimulation, sleep disruption, unmeasured hormonal effects. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Serum pregnenolone | No independently validated target; track change from own baseline | Confirms the dose is absorbed and quantifies the size of the change |
| DHEA sulfate | Men 350–500 µg/dL; women 200–300 µg/dL | Shows whether the androgen branch downstream of pregnenolone is being pushed |
| Total and free testosterone | Men 600–900 ng/dL total; women 30–70 ng/dL total | Detects androgenic conversion before acne or hair loss appear |
| Estradiol | Men 20–30 pg/mL; premenopausal women interpreted against cycle day; postmenopausal women under 30 pg/mL | Detects estrogenic conversion, the relevant concern in hormone-sensitive conditions |
| Progesterone | Women, mid-luteal 10–20 ng/mL; men under 1.0 ng/mL | Pregnenolone converts directly to progesterone, so this is the closest downstream marker |
| Morning cortisol | 10–18 µg/dL drawn between 7 and 9 a.m. | Pregnenolone supplies substrate for cortisol; confirms the adrenal axis is not being driven |
| Sex hormone-binding globulin | 20–60 nmol/L in both sexes | Determines the free, active fraction of any hormone change seen above |
| Prostate-specific antigen (men 40 and over) | Under 1.0 ng/mL before age 60, under 1.5 ng/mL thereafter; annual rise under 0.35 ng/mL | Laboratory work shows pregnenolone drives growth of androgen-receptor-mutant prostate cancer cells |
| Thyroid-stimulating hormone with free thyroxine | Thyroid-stimulating hormone 0.5–2.0 mIU/L; free thyroxine in the upper half of the laboratory range | Blended adrenal-support products carry undeclared triiodothyronine |
| Resting blood pressure and pulse | Under 120/80 mmHg; resting pulse 50–70 beats per minute | Palpitations are reported, and autonomic stress reactivity changes measurably on pregnenolone |
Cadence: Baseline panel before the first dose; full hormone panel repeated at 8–12 weeks, then every 6 months while use continues; blood pressure and pulse weekly during titration and monthly thereafter; prostate-specific antigen annually in men.